Search Results - "Schoemaker, R.C"

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers by Boot, J.D, De Haas, S.L, Van Gerven, J.M.A, De Smet, M, Leathem, T, Wagner, J, Denker, A, Miller, D, Van Doorn, M.B.A, Schoemaker, R.C, Cohen, A.F, Diamant, Z

“…Abstract Background MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive…”
Get full text

Reversal of the late asthmatic response increases exhaled nitric oxide by Boot, J.D., Tarasevych, S., Sterk, P.J., Schoemaker, R.C., Wang, L., Amin, D., Cohen, A.F., Diamant, Z.

“…A clear-cut relationship of eNO and the airway calibre may have implications for the measurements.7-10 Late asthmatic airway response (LAR) to inhaled…”
Get full text

Analysis of asymmetry of agonist concentration–effect curves by Van der Graaf, P.H., Schoemaker, R.C.

“…We have developed a fitting procedure, based on nonlinear mixed effect modelling and original work by Richards (1959)( J Exp Botany 10, 290–300), to describe…”
Get full text

Effect of intrapulmonary tetrahydrocannabinol administration in humans by Zuurman, L., Roy, C., Schoemaker, RC, Hazekamp, A., den Hartigh, J., Bender, JCME, Verpoorte, R., Pinquier, JL, Cohen, AF, van Gerven, JMA

“…This randomised, double-blind, placebo-controlled, cross-over study was designed to identify which pharmacodynamic parameters most accurately quantify the…”
Get full text

Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids by Strougo, A., Zuurman, L., Roy, C., Pinquier, JL, van Gerven, JMA, Cohen, AF, Schoemaker, RC

“…Pharmacokinetics after pulmonary administration of δ-9-tetrahydrocannabinol (THC) and its major metabolites 11-OH-THC and 11-nor-9-COOH-THC was quantified…”
Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., de Smet, M., Schoemaker, R.C., Rijnbeek, B., Cohen, A.F., Vega, J.M., Agrawal, N.G.B., Goel, T.V., Simpson, R.C., Pearson, L.K., Li, S., Hesney, M., Murphy, M.G., van Gerven, J.M.A.

“…TPA023, a GABAA α2,3 αsubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating effects…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., Schoemaker, R.C., van Dyck, K., Murphy, M.G., de Smet, M., Vessey, L.K., Ramakrishnan, R., Xue, L., Cohen, A.F., van Gerven, J.M.A.

“…The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
Get full text

Pharmacokinetics of rectal tramadol in postoperative paediatric patients by Zwaveling, J., Bubbers, S., van Meurs, A.H.J., Schoemaker, R.C., van Heel, I. Ruijs-Dudok, Vermeij, P., Burggraaf, J.

“…Postoperative analgesia in children may be improved by using tramadol. The pharmacokinetics of rectal tramadol in young children were therefore investigated…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA A α 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., Schoemaker, R.C., van Dyck, K., Murphy, M.G., de Smet, M., Vessey, L.K., Ramakrishnan, R., Xue, L., Cohen, A.F., van Gerven, J.M.A.

“…The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA a2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S.L, de Visser, S.J, van der Post, J.P, Schoemaker, R.C, van Dyck, K, Murphy, M.G, de Smet, M, Vessey, L.K, Ramakrishnan, R, Xue, L, Cohen, A.F, van Gerven, J.M.A

Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GAB[A.sub.A] [α.sub.2,3] subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S.L, de Visser, S.J, van der Post, J.P, de Smet, M, Schoemaker, R.C, Rijnbeek, B, Cohen, A.F, Vega, J.M, Agrawal, N.G.B, Goel, T.V, Simpson, R.C, Pearson, L.K, Li, S, Hesney, M, Murphy, M.G, van Gerven, J.M.A

Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA A α 2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., de Smet, M., Schoemaker, R.C., Rijnbeek, B., Cohen, A.F., Vega, J.M., Agrawal, N.G.B., Goel, T.V., Simpson, R.C., Pearson, L.K., Li, S., Hesney, M., Murphy, M.G., van Gerven, J.M.A.

“…TPA023, a GABA A α2,3 αsubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating effects…”
Get full text

Peribulbar Corticosteroid Injection: Vitreal and Serum Concentrations After Dexamethasone Disodium Phosphate Injection by WEIJTENS, O., VAN DER SLUIJS, F.A., SCHOEMAKER, R.C., LENTJES, E.G.W.M., COHEN, A.F., ROMIJN, F.P.H.T.M., VAN MEURS, J.C.

“…To study the dexamethasone level reached in human vitreous after a peribulbar injection of 5 mg of dexamethasone disodium phosphate and to assess its systemic…”
Get full text

Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery by VAN DER VORST, M. M. J, VAN HEEL, I. Ruys-Dudok, KIST-VAN HOLTHE, J. E, DEN HARTIGH, J, SCHOEMAKER, R. C, COHEN, A. F, BURGGRAAF, J

“…The commonly used continuous intravenous (i.v.) furosemide dosing schedule after cardiac surgery in children is largely empirical and may not be optimal. This…”
Get full text

Influence of obesity and body fat distribution on growth hormone kinetics in humans by Langendonk, J.G, Meinders, A.E, Burggraaf, J, Frolich, M, Roelen, C.A.M, Schoemaker, R.C, Cohen, A.F, Pijl, H

“…We studied the kinetics of exogenous recombinant 22-kDa human growth hormone (rhGH) in premenopausal women with upper body obesity (UBO), lower body obesity…”
Get full text

R-195. Bioequivalence of subcutaneous injection of recombinant human follicle stimulating hormone by Puregon® Pen injection and conventional syringe by Voortman, G., van de Post, L., Schoemaker, R.C., van Gerven, J.M.A.

Get full text

Sorbitol as a marker for drug-induced decreases of variable duration in liver blood flow in healthy volunteers by Burggraaf, J, Schoemaker, R.C, Lentjes, E.G.W.M, Cohen, A.F

“…Objective: Sorbitol has been suggested as a suitable marker to assess liver blood flow (LBF), after it was shown to adequately reflect prolonged changes in LBF…”
Get full text

Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer by Schiphorst, P. P., Chang, P. C., Clar, N., Schoemaker, R. C., Osanto, S.

“…Background: Most patients with metastatic renal cell carcinoma (RCC) have undergone unilateral- and some bilateral nephrectomy. Because interleukin-2 (IL-2) is…”
Get full text

The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers by FAAIJ, R. A, VAN GRIENSVEN, J. M. T, SCHOEMAKER, R. C, GOGGIN, T, GUENZI, A, KROON, J. M, BURGGRAAF, J, COHEN, A. F

“…The effect of oral warfarin on the pharmacokinetics and pharmacodynamics of the synthetic direct thrombin inhibitor napsagatran was investigated. In an open,…”
Get full text

Concentration-Effect-Relationships of Two Infusion Rates of Rilmenidine, for Blood Pressure and Sedation in Healthy Subjects by Gerven, J.M.A., Dubar, M., Frey, N., Schoemaker, R.C., Jochemsen, R., Cohen, A.F.

“…Clinical Pharmacology & Therapeutics (1999) 65, 133–133; doi:…”
Get full text